XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition
 6 Months Ended
Jun. 30, 2020
Revenue Recognition [Abstract]  
Revenue Recognition

9. Revenue Recognition

All of our product revenue consisted of sales of HEPLISAV-B in the U.S. For the six months ended June 30, 2020 and 2019, our three largest Customers collectively represented approximately 66% and 64% of our product revenue, respectively. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2020 (in thousands):

 

 

 

Balance at

Beginning of

Period

 

 

Provisions

related to current

period sales

 

 

Credit or

payments

made during

the period

 

 

Balance

at End of

Period

 

Six months ended June 30, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves(1)

 

$

2,701

 

 

$

3,594

 

 

$

(4,230

)

 

$

2,065

 

Revenue reserve accruals(2)

 

$

3,893

 

 

$

2,793

 

 

$

(2,816

)

 

$

3,870

 

 

(1)

Reserves are for chargebacks, discounts and other fees.

(2)

Accruals are for returns, rebates and other fees.